Files and links (1)
Published, Version of Record (VoR)Open Access (License Unspecified), Open
Journal article
Disease modifying drugs targeting β-amyloid
American journal of Alzheimer's disease and other dementias, v 27(5)
Aug 2012
PMID: 22815077
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
At this time there are no effective methods to alter the disease course in Alzheimer's disease. All FDA approved interventions are for symptomatic relief only. However, it is an exciting time as many agents in development have theorhetical potential to impact the disease course. This review discusses some of the agents that have been in clinical trials, particularly those that affect amyloid processing. Some agents have failed while others still provide hope. Since amyloid is the peptide most closely linked to disease pathogenesis, it is possible that some of the anti-amyloid agents will impact the disease progression in a meaningful way.
Metrics
Details
- Title
- Disease modifying drugs targeting β-amyloid
- Creators
- S N Ozudogru - Drexel UniversityC F Lippa - Drexel University
- Publication Details
- American journal of Alzheimer's disease and other dementias, v 27(5)
- Publisher
- Sage
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000306556700003
- Scopus ID
- 2-s2.0-84864232926
- Other Identifier
- 991019312468004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Clinical Neurology
- Geriatrics & Gerontology